Brian Peter Zambrowicz
Direktor/Vorstandsmitglied bei Texas A&M Institute for Genomic Medicine
Profil
Brian Peter Zambrowicz is the founder of Lexicon Pharmaceuticals, Inc. which was founded in 1995.
He held the title of Chief Scientific Officer & Executive VP from 2011 to 2015.
Currently, he is the Director at Texas A&M Institute for Genomic Medicine.
He previously worked as a Director & Senior Scientific Advisor at Nuevolution AB.
Dr. Zambrowicz earned a doctorate degree from the University of Washington and an undergraduate degree from the University of Wisconsin.
Aktive Positionen von Brian Peter Zambrowicz
Unternehmen | Position | Beginn |
---|---|---|
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Brian Peter Zambrowicz
Unternehmen | Position | Ende |
---|---|---|
LEXICON PHARMACEUTICALS, INC. | Gründer | 24.02.2015 |
NUEVOLUTION AB (PUBL) | Direktor/Vorstandsmitglied | - |
Ausbildung von Brian Peter Zambrowicz
University of Washington | Doctorate Degree |
University of Wisconsin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LEXICON PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Nuevolution AB
Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |